Acute Infectious Encephalitis and Myelitis in Guadeloupe by New Generation Sequencing
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age28+
SponsorCentre Hospitalier Universitaire de la Guadeloupe
About this trial
: Encephalitis or myelitis is defined as the inflammatory or infectious involvement of the cerebral parenchyma or spinal cord. When an infectious origin is suspected, the germ is not always identified. Next-generation sequencing could be used to correct an etiological diagnosis of these severe conditions in Guadeloupe. The rate of cases for which the infectious agent is not identified encourages continued diagnostic efforts, with the objective of identifying new pathogens or emerging pathogens, some of which may be more specific in the tropics.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patient of at least 28 days of life
With acute onset of symptoms for more than 24 hours
a disorder of consciousness or alertness
memory disorder
Disqualifiers
Primary vasculitis of the central nervous system or a documented specific impairment in an autoimmune condition
Cerebral thrombophlebitis if not associated with encephalitis
Meningitis without clinical or paraclinical argument for cerebral parenchymal involvement
Pyogenic abscess
Trial population
Patients with suspected acute infectious encephalitis and / or myelitis, according to the clinical and paraclinical criteria described in recommendations of the International Encephalitis Consortium in 2013 and the by the Transverse Myelitis Consortium Working Group in 2002
Trial design
Design model
Case-only
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
100 Participants
are grouped into 1 trial groupGroup A: Encephalitis or myelitis
Trial outcomes
Primary outcomes
1
neurotropic pathogen
The detection of a neurotropic pathogen in the cerebrospinal fluid
Time frame
baseline, 3 month (if necessary)Secondary outcomes
1
Neuro radiological
Neuro radiological observations
Time frame
baseline, 3 month, 12 month2
Bacteriological
Bacteriological observations
Time frame
baseline, 15 days , 3 months3
biochimical
biochimical observations
Time frame
baseline, 15 days, 3 months4
Clinical neurological
Clinical neurological examination
Time frame
at day 0, at hospital discharge or maximum on the 15th day (+/- 30 days), and 3 months, 12 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov